In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation

PurposeTo assess the efficiency of IVM in patients with repeated ART failure due to resistant ovary syndrome or due to deficient oocyte maturation.MethodsClinical and laboratory data were obtained retrospectively from 28 patients who underwent 49cycles of IVM between 2010 and 2017; nine patients had resistant ovary syndrome and 19 patients had repeated deficient oocyte maturation.ResultsNine patients with resistant ovary syndrome underwent 24 IVM cycles. In those, an average of 11.510.4 cumulus-oocyte complexes (COC) was retrieved, and IVM resulted in 3.43.1 mature oocytes. After ICSI and transfer of 23 cleavage-stage embryos, eight pregnancies were obtained, resulting in five healthy live births. The live birth rate was 16.7% per started cycle and 33.3% per patientineteen patients with a history of deficient oocyte maturation underwent 25 IVM cycles. An average of 10.6 +/- 9.2 COC was retrieved, and after IVM, 1.3 +/- 2.1 oocytes were mature. No mature oocytes were obtained in 11cycles. In ten cycles with mature oocytes, none of them fertilized after ICSI. Out of four cycles with fertilized oocytes, only one good-quality embryo was obtained. No live births were obtained after IVM in patients with a history of deficient oocyte maturation.ConclusionsBased on our experience, IVM is a valuable approach in patients with resistant ovary syndrome, but should not be recommended for patients with deficient oocyte maturation.